FindTrial
Sign In

Exploring the Mechanism by which Resistin Inhibits Osteoarthritis through Alleviating Mitochondrial Damage Based on VDAC1 Palmitoylation Modification

Exploring the Mechanism by which Resistin Inhibits Osteoarthritis through Alleviating Mitochondrial Damage Based on VDAC1 Palmitoylation Modification

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600129040
Enrollment
Unknown
Registered
2026-07-29
Start date
2026-09-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Interventions

Normal group:None
OA group:None

Sponsors

The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou,China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 90 Years

Inclusion criteria

Inclusion criteria: Normal group: patients undergoing amputation and joint replacement surgery; OA group: patients with OA undergoing total knee replacement surgery

Exclusion criteria

Exclusion criteria: Normal group: patients diagnosed with arthritis; incomplete clinical data; OA group: incomplete clinical data

Design outcomes

Primary

MeasureTime frame
nlrp3;vdac1;mmp13;—

Countries

China

Contacts

Public ContactJingjing Shang

The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou,China

Shang0308@126.com+86 139 2103 2480

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026